Abbott Laboratories

NYSE:ABT Stock Report

Market Cap: US$166.9b

Abbott Laboratories Past Earnings Performance

Past criteria checks 2/6

Abbott Laboratories has been growing earnings at an average annual rate of 10.4%, while the Medical Equipment industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 0.9% per year. Abbott Laboratories's return on equity is 11.9%, and it has net margins of 13.9%.

Key information

10.45%

Earnings growth rate

10.94%

EPS growth rate

Medical Equipment Industry Growth8.90%
Revenue growth rate0.86%
Return on equity11.91%
Net Margin13.85%
Next Earnings Update16 Jul 2026

Recent past performance updates

Recent updates

Seeking Alpha • Jul 03

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

Summary Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution. ABT's resilient balance sheet, improving core business trends, and strategic positioning support a contrarian recovery thesis toward former share price highs. Read the full article on Seeking Alpha
Analysis Article • Jun 21

Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings

Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus Recent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock. The reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around...
Narrative Update • Jun 16

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower from about $117.29 to $116.54, reflecting a series of reduced Street price targets that cite utilization and inflation headwinds, while still applying a modestly lower discount rate and a slightly softer future P/E assumption. Analyst Commentary Recent Street research on Abbott Laboratories points to a more cautious tone, with many price targets cut and utilization and inflation flagged as key issues.
Narrative Update • Jun 02

ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing

Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.
Narrative Update • May 12

ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.
Narrative Update • Apr 23

ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing

Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.
Narrative Update • Apr 09

ABT: AF Portfolio And Dividend Track Record Will Support Future Upside

Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.
Narrative Update • Mar 26

ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside

Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.
Narrative Update • Mar 11

ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside

Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.
Narrative Update • Feb 24

ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside

Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.
Narrative Update • Feb 10

ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside

Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.
Narrative Update • Jan 26

ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential

Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.
Narrative Update • Jan 11

ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside

Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.
Analysis Article • Jan 03

Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
Narrative Update • Dec 27

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns

Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.
Narrative Update • Dec 12

ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside

Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.
Narrative Update • Nov 28

ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside

Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.
Narrative Update • Nov 14

ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains

Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.
Analysis Article • Nov 05

Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem

Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Narrative Update • Oct 31

ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead

Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.
Narrative Update • Oct 16

Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds

Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.
Analysis Article • Sep 15

There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

With a price-to-earnings (or "P/E") ratio of 16.7x Abbott Laboratories ( NYSE:ABT ) may be sending bullish signals at...
Seeking Alpha • Apr 16

Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices

Summary I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth. Despite geopolitical risks in China, Abbott's cost management and margin expansion support the ABT stock double-digit EPS growth guidance for FY25. Read the full article on Seeking Alpha
Seeking Alpha • Mar 16

Abbott Laboratories Basking In A Sharp Turn In Sentiment

Summary Abbott Laboratories' stock has surged 25% in eight months, outperforming peers on strong medical device growth and perhaps market rotation to names with less perceived macro and geopolitical risk. Fourth quarter results showed 9% organic revenue growth, with medical devices leading at 14%, and improved profit margins. Abbott's medical device business is executing well, with double-digit growth in structural heart and diabetes, and above-peer results across most of the business. An important legal victory could signal lower overall risk in its infant nutrition litigation, while a lackluster trial result from a rival could re-energize the outlook for TriClip. Valuation is more challenging now, as it takes a pretty aggressive bull-case model to find significant fundamentals-driven upside. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Abbott Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:ABT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2645,1346,25212,2972,940
31 Dec 2544,3286,50011,6302,889
30 Sep 2543,84313,97511,4872,935
30 Jun 2543,10913,97711,3442,882
31 Mar 2542,34413,50011,1962,855
31 Dec 2441,95013,40011,1092,823
30 Sep 2441,2175,76110,9212,673
30 Jun 2440,7255,54610,7622,632
31 Mar 2440,3265,60810,5702,649
31 Dec 2340,1095,70010,3852,619
30 Sep 2339,9595,14210,5832,619
30 Jun 2340,2265,14010,6112,729
31 Mar 2341,5055,78510,6572,698
31 Dec 2243,6536,90510,7032,741
30 Sep 2245,0307,85710,9012,921
30 Jun 2245,5488,52010,9712,811
31 Mar 2244,5147,69510,9782,781
31 Dec 2143,0757,04211,0062,738
30 Sep 2142,3087,20810,5932,623
30 Jun 2140,2336,34310,2442,531
31 Mar 2137,3385,6939,8072,441
31 Dec 2034,6084,4499,5912,420
30 Sep 2032,2213,3469,4052,289
30 Jun 2031,4443,0739,4402,305
31 Mar 2032,0953,5399,5972,318
31 Dec 1931,9043,6669,5402,440
30 Sep 1931,3553,2729,4522,395
30 Jun 1930,9352,8679,4032,373
31 Mar 1930,7232,5829,4482,371
31 Dec 1830,5782,3199,5682,298
30 Sep 1830,4028029,4822,280
30 Jun 1829,5758129,1412,274
31 Mar 1828,4453658,8682,219
31 Dec 1727,3903448,8042,183
30 Sep 1725,1341,9718,1751,979
30 Jun 1723,6071,0557,8081,763
31 Mar 1722,3031,3847,3951,575
31 Dec 1620,8531,0566,5581,442
30 Sep 1620,7089896,6201,353
30 Jun 1620,5561,9396,6581,379
31 Mar 1620,3932,1246,6481,392
31 Dec 1520,4052,5866,7421,371
30 Sep 1520,5732,5236,5931,338

Quality Earnings: ABT has high quality earnings.

Growing Profit Margin: ABT's current net profit margins (13.9%) are lower than last year (31.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ABT's earnings have grown by 10.4% per year over the past 5 years.

Accelerating Growth: ABT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ABT had negative earnings growth (-53.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (14.8%).

Return on Equity

High ROE: ABT's Return on Equity (11.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/08 21:55
End of Day Share Price 2026/07/08 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbott Laboratories is covered by 52 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
David RescottBaird
Adam FeinsteinBarclays